Symptomatic burden amongst myeloproliferative neoplasm patients: MPN-10 prospective assessment in a Portuguese cohort
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S2183-69142021000200026 |
Resumo: | Abstract Introduction: Myeloproliferative neoplasms (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), significantly impact patients’ quality of life (QoL). The symptom burden assessment and continuous monitoring using the MPN Symptom Assessment Form Total Symptom Score (MPN-10) allows detecting symptomatic changes that may be signs of disease progression and can be used as an indicator of the need to reassess disease progression and/or therapeutic approach. Methods: Prospective multicenter registry of Portuguese MPN patients, including patients’ demographics and clinical characterization, and disease symptomatic burden based on MPN-10. Results: Overall, 324 patients were included, male to female ratio 0.7:1, median age 71 years old, median disease duration >3 years. Most patients had ET (63%), 24% PV, and 13% MF. Around 70% were being treated with hydroxyurea, 31% were on recommended low-dose aspirin, 9% needed phlebotomy, 4% received ruxolitinib, and <2% interferon. Most reported symptoms include fatigue, inactivity, itching, and concentration problems. PV and ET patients’ total symptom score significantly improved from baseline until last follow-up visit. The itching had a significant improvement over baseline for PV patients, as did fatigue, inactivity, concentration problems, and night sweats in ET patients. Conclusions: The systematic application of the MPN-10 led to a more in-depth knowledge of patients and their symptoms, which, together with analytical changes, motivated therapeutic readjustments that led to QoL gains. Future analysis of this cohort should be conducted to refine these results. |
id |
RCAP_f4ff0ca25cddf4e728fa1c54a294de27 |
---|---|
oai_identifier_str |
oai:scielo:S2183-69142021000200026 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Symptomatic burden amongst myeloproliferative neoplasm patients: MPN-10 prospective assessment in a Portuguese cohortDisease managementMPN-10Myeloproliferative neoplasmsQuality of lifeSymptomsAbstract Introduction: Myeloproliferative neoplasms (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), significantly impact patients’ quality of life (QoL). The symptom burden assessment and continuous monitoring using the MPN Symptom Assessment Form Total Symptom Score (MPN-10) allows detecting symptomatic changes that may be signs of disease progression and can be used as an indicator of the need to reassess disease progression and/or therapeutic approach. Methods: Prospective multicenter registry of Portuguese MPN patients, including patients’ demographics and clinical characterization, and disease symptomatic burden based on MPN-10. Results: Overall, 324 patients were included, male to female ratio 0.7:1, median age 71 years old, median disease duration >3 years. Most patients had ET (63%), 24% PV, and 13% MF. Around 70% were being treated with hydroxyurea, 31% were on recommended low-dose aspirin, 9% needed phlebotomy, 4% received ruxolitinib, and <2% interferon. Most reported symptoms include fatigue, inactivity, itching, and concentration problems. PV and ET patients’ total symptom score significantly improved from baseline until last follow-up visit. The itching had a significant improvement over baseline for PV patients, as did fatigue, inactivity, concentration problems, and night sweats in ET patients. Conclusions: The systematic application of the MPN-10 led to a more in-depth knowledge of patients and their symptoms, which, together with analytical changes, motivated therapeutic readjustments that led to QoL gains. Future analysis of this cohort should be conducted to refine these results.Associação de Enfermagem Oncológica Portuguesa (AEOP)2021-12-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2183-69142021000200026Revista Onconews n.43 2021reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2183-69142021000200026Sarmento,MariaPonte,SandraMonteiro,Maria JoséMoura,ZildaFerreira,Giselainfo:eu-repo/semantics/openAccess2024-02-06T17:31:17Zoai:scielo:S2183-69142021000200026Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:34:28.291352Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Symptomatic burden amongst myeloproliferative neoplasm patients: MPN-10 prospective assessment in a Portuguese cohort |
title |
Symptomatic burden amongst myeloproliferative neoplasm patients: MPN-10 prospective assessment in a Portuguese cohort |
spellingShingle |
Symptomatic burden amongst myeloproliferative neoplasm patients: MPN-10 prospective assessment in a Portuguese cohort Sarmento,Maria Disease management MPN-10 Myeloproliferative neoplasms Quality of life Symptoms |
title_short |
Symptomatic burden amongst myeloproliferative neoplasm patients: MPN-10 prospective assessment in a Portuguese cohort |
title_full |
Symptomatic burden amongst myeloproliferative neoplasm patients: MPN-10 prospective assessment in a Portuguese cohort |
title_fullStr |
Symptomatic burden amongst myeloproliferative neoplasm patients: MPN-10 prospective assessment in a Portuguese cohort |
title_full_unstemmed |
Symptomatic burden amongst myeloproliferative neoplasm patients: MPN-10 prospective assessment in a Portuguese cohort |
title_sort |
Symptomatic burden amongst myeloproliferative neoplasm patients: MPN-10 prospective assessment in a Portuguese cohort |
author |
Sarmento,Maria |
author_facet |
Sarmento,Maria Ponte,Sandra Monteiro,Maria José Moura,Zilda Ferreira,Gisela |
author_role |
author |
author2 |
Ponte,Sandra Monteiro,Maria José Moura,Zilda Ferreira,Gisela |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Sarmento,Maria Ponte,Sandra Monteiro,Maria José Moura,Zilda Ferreira,Gisela |
dc.subject.por.fl_str_mv |
Disease management MPN-10 Myeloproliferative neoplasms Quality of life Symptoms |
topic |
Disease management MPN-10 Myeloproliferative neoplasms Quality of life Symptoms |
description |
Abstract Introduction: Myeloproliferative neoplasms (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), significantly impact patients’ quality of life (QoL). The symptom burden assessment and continuous monitoring using the MPN Symptom Assessment Form Total Symptom Score (MPN-10) allows detecting symptomatic changes that may be signs of disease progression and can be used as an indicator of the need to reassess disease progression and/or therapeutic approach. Methods: Prospective multicenter registry of Portuguese MPN patients, including patients’ demographics and clinical characterization, and disease symptomatic burden based on MPN-10. Results: Overall, 324 patients were included, male to female ratio 0.7:1, median age 71 years old, median disease duration >3 years. Most patients had ET (63%), 24% PV, and 13% MF. Around 70% were being treated with hydroxyurea, 31% were on recommended low-dose aspirin, 9% needed phlebotomy, 4% received ruxolitinib, and <2% interferon. Most reported symptoms include fatigue, inactivity, itching, and concentration problems. PV and ET patients’ total symptom score significantly improved from baseline until last follow-up visit. The itching had a significant improvement over baseline for PV patients, as did fatigue, inactivity, concentration problems, and night sweats in ET patients. Conclusions: The systematic application of the MPN-10 led to a more in-depth knowledge of patients and their symptoms, which, together with analytical changes, motivated therapeutic readjustments that led to QoL gains. Future analysis of this cohort should be conducted to refine these results. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-12-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S2183-69142021000200026 |
url |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S2183-69142021000200026 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S2183-69142021000200026 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação de Enfermagem Oncológica Portuguesa (AEOP) |
publisher.none.fl_str_mv |
Associação de Enfermagem Oncológica Portuguesa (AEOP) |
dc.source.none.fl_str_mv |
Revista Onconews n.43 2021 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137401376866304 |